I've been working on this area for quite long, and I think it's just a matter of time it becomes huge. Right now, a major roadblock is that single-cell RNA-seq, which may also give paired TCR alpha and beta chain data, is too expensive compared to bulk TCR-seq. The latter has limited resolution and more technical variability.
However, Microsoft Research has a preprint that employs bulk TCR-seq where they are able to detect Lyme, which is particularly difficult to do using antibody assays and often mistaken for multiple sclerosis: https://www.medrxiv.org/content/10.1101/2021.07.30.21261353v...
AFAIK, there are a few startups in stealth mode and non-stealth mode collecting big repertoire datasets. In those datasets, one can even measure the effects of vaccinations that occurred decades ago.
However, Microsoft Research has a preprint that employs bulk TCR-seq where they are able to detect Lyme, which is particularly difficult to do using antibody assays and often mistaken for multiple sclerosis: https://www.medrxiv.org/content/10.1101/2021.07.30.21261353v...
AFAIK, there are a few startups in stealth mode and non-stealth mode collecting big repertoire datasets. In those datasets, one can even measure the effects of vaccinations that occurred decades ago.